Mike van der Have1, Tim D G Belderbos2, Herma H Fidder2, Max Leenders2, Gerard Dijkstra3, Charlotte P Peters4, Emma J Eshuis4, Cyriel Y Ponsioen4, Peter D Siersema2, Martijn G H van Oijen2, Bas Oldenburg2. 1. Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: M.vanderhave85@gmail.com. 2. Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Netherlands. 3. Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. 4. Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Abstract
BACKGROUND: Screening for opportunistic infections prior to starting biological therapy in patients with inflammatory bowel disease is recommended. AIMS: To assess adherence to screening for opportunistic infections prior to starting biological therapy in Crohn's disease patients and its yield. METHODS: A multicentre retrospective study was conducted in Crohn's disease patients in whom infliximab or adalimumab was started between 2000 and 2010. Screening included tuberculin skin test, interferon-gamma release assay or chest X-ray for tuberculosis. Extended screening included screening for tuberculosis and viral infections. Patients were followed until three months after ending treatment. Primary endpoints were opportunistic and serious infections. RESULTS: 611 patients were included, 91% on infliximab. 463 (76%) patients were screened for tuberculosis, of whom 113 (24%) underwent extended screening. Screening for tuberculosis and hepatitis B increased to, respectively, 90-97% and 36-49% in the last two years. During a median follow-up of two years, 64/611 (9%, 3.4/100 patient-years) opportunistic infections and 26/611 (4%, 1.6/100 patient-years) serious infections were detected. Comorbidity was significantly associated with serious infections (hazard ratio 3.94). CONCLUSIONS: Although screening rates for tuberculosis and hepatitis B increased, screening for hepatitis B was still suboptimal. More caution is required when prescribing biologicals in patients with comorbid conditions.
BACKGROUND: Screening for opportunistic infections prior to starting biological therapy in patients with inflammatory bowel disease is recommended. AIMS: To assess adherence to screening for opportunistic infections prior to starting biological therapy in Crohn's diseasepatients and its yield. METHODS: A multicentre retrospective study was conducted in Crohn's diseasepatients in whom infliximab or adalimumab was started between 2000 and 2010. Screening included tuberculin skin test, interferon-gamma release assay or chest X-ray for tuberculosis. Extended screening included screening for tuberculosis and viral infections. Patients were followed until three months after ending treatment. Primary endpoints were opportunistic and serious infections. RESULTS: 611 patients were included, 91% on infliximab. 463 (76%) patients were screened for tuberculosis, of whom 113 (24%) underwent extended screening. Screening for tuberculosis and hepatitis B increased to, respectively, 90-97% and 36-49% in the last two years. During a median follow-up of two years, 64/611 (9%, 3.4/100 patient-years) opportunistic infections and 26/611 (4%, 1.6/100 patient-years) serious infections were detected. Comorbidity was significantly associated with serious infections (hazard ratio 3.94). CONCLUSIONS: Although screening rates for tuberculosis and hepatitis B increased, screening for hepatitis B was still suboptimal. More caution is required when prescribing biologicals in patients with comorbid conditions.
Authors: Eva C Schwaneck; Manuel Krone; Sonja Kreissl-Kemmer; Benedikt Weißbrich; Johannes Weiss; Hans-Peter Tony; Ottar Gadeholt; Marc Schmalzing; Andreas Geier Journal: Clin Rheumatol Date: 2018-09-20 Impact factor: 2.980
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Rajesh Shah; Edith Y Ho; Jennifer R Kramer; Peter Richardson; Shubhada Sansgiry; Hashem B El-Serag; Jason K Hou Journal: Dig Dis Sci Date: 2018-04-16 Impact factor: 3.199
Authors: Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany Journal: Jt Comm J Qual Patient Saf Date: 2019-01-25
Authors: Gabriela Schmajuk; Chris Tonner; Laura Trupin; Jing Li; Urmimala Sarkar; Dana Ludwig; Stephen Shiboski; Marina Sirota; R Adams Dudley; Sara Murray; Jinoos Yazdany Journal: Medicine (Baltimore) Date: 2017-03 Impact factor: 1.889
Authors: Vera E R Asscher; Vince B C Biemans; Marieke J Pierik; Gerard Dijkstra; Mark Löwenberg; Sander van der Marel; Nanne K H de Boer; Alexander G L Bodelier; Jeroen M Jansen; Rachel L West; Jeoffrey J L Haans; Willemijn A van Dop; Rinse K Weersma; Frank Hoentjen; P W Jeroen Maljaars Journal: Aliment Pharmacol Ther Date: 2020-09-09 Impact factor: 8.171